PhRMA II
George Scangos has been appointed Chairman-Elect of the PhRMA Board of Directors.
He served as CEO, Biogen Idec, since June 2010, when he joined the company from a role as CEO and President of Exelixis.
He previously held senior positions in R&D and biotechnology at Bayer. He began his career with a PhD from the University of Massachusetts and a Professorship of biology at Johns Hopkins.
"The accelerating pace of science, an increased understanding of the biology of disease and the use of emerging technologies are combining to enable meaningful advances in treating some of the world's most intractable diseases," said Scangos.
"Developing breakthrough medicines requires creative policy solutions that ensure scientific discoveries are translated into treatments for patients as quickly as possible – and that these treatments contribute to a more productive and prosperous society."
(Image: Biogen Idec)